~ Ponatinib to be Featured in Fourteen Presentations
~ Company to Host Investor Meeting and Webcast with Dr. Moshe Talpaz
on Monday, December 12 at 7 a.m (PST)
CAMBRIDGE, Mass., Nov 17, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that interim
clinical data from the fully enrolled, pivotal PACE trial of its
investigational, pan-BCR-ABL inhibitor, ponatinib,
will be presented at the 53rd Annual Meeting of the American Society of
Hematology (ASH) being held in San Diego, December 10-13, 2011. The
interim findings from the PACE trial will be featured in an oral
presentation on Sunday, December 11 and also will be highlighted in an
investor meeting to be webcast live from San Diego. This trial is being
conducted in patients with chronic myeloid leukemia (CML) and
Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL)
who are resistant or intolerant to either nilotinib or dasatinib, two
currently available CML therapies, or those who have the T315I mutation
of BCR-ABL for which no current treatments are known to be effective.
Thirteen additional abstracts describing clinical and non-clinical work
on ponatinib will also be presented at the meeting.
Oral Presentation of Interim Data from PACE Trial
|
Title:
|
|
Initial Findings from the PACE Trial: A Pivotal Phase 2 Study of
Ponatinib in Patients with CML and Ph+ALL Resistant or Intolerant
to Dasatinib or Nilotinib, or with the T315I Mutation
|
|
Oral Session:
|
|
Chronic Myeloid Leukemia - Therapy: Resistance to Tyrosine Kinase
Inhibitors
|
|
Date & Time:
|
|
Sunday, December 11, 2011, 4:30 p.m. (PST)
|
|
Abstract No.:
|
|
109
|
|
Presenter:
|
|
Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer
Center)
|
|
Location:
|
|
Ballroom 20BC
|
Investor Meeting and Webcast
A breakfast meeting to review the interim PACE trial data with research
analysts and institutional investors will feature Moshe Talpaz, M.D.,
Associate Director of Translational Research and Associate Chief of
Hematologic Malignancies, Trotman Professor of Leukemia Research at the
University of Michigan Medical Center, and members of ARIAD's
management. Dr. Talpaz has been an investigator in the Phase 1 and Phase
2 trials of ponatinib. This meeting will be webcast live and can be
accessed by visiting the investor relations section of the Company's
website at investor.ariad.com
or dialing: 866.770.7125 (domestic) or 617.213.8066 (international) and
providing the pass code 91497220.
|
Date:
|
|
Monday, December 12, 2011
|
|
|
|
|
Time:
|
|
7:00 a.m. to 8:00 a.m. (PST)
|
|
|
|
|
Location:
|
|
The Westin Gaslamp Quarter Hotel, Santa Fe Conference Room
|
To attend the meeting, please RSVP to Investor.breakfast@ariad.com
by Wednesday, December 7, 2011.
A replay of this investor event will be available on the ARIAD website
approximately three hours after the presentation and will be archived
for four weeks. To ensure a timely connection to the live webcast,
participants should log onto the webcast at least 15 minutes prior to
the scheduled start time.
The following presentations are included among the 14 presentations
at ASH to feature clinical and non-clinical data on ponatinib.
|
Title:
|
|
Subset Analysis of Response to Treatment of Chronic Phase CML in a
Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies
|
|
Oral Session:
|
|
Chronic Myeloid Leukemia - Therapy: New Drugs, New Procedures
|
|
Date & Time:
|
|
Monday, December 12, 2011, 3:00 p.m. (PST)
|
|
Abstract No.:
|
|
602
|
|
Presenter:
|
|
Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer
Center)
|
|
Location:
|
|
Ballroom 20BC
|
|
|
|
|
Title:
|
|
ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to
Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase
Inhibitor, Ponatinib
|
|
Poster Session:
|
|
Chronic Myeloid Leukemia - Biology and Pathophysiology, Excluding
Therapy: Poster II
|
|
Date & Time:
|
|
Sunday, December 11, 2011, 6:00 - 8:00 p.m. (PST)
|
|
Abstract No.:
|
|
2745
|
|
Presenter:
|
|
Deborah White, Ph.D. (University of Adelaide, Australia)
|
|
Location:
|
|
Hall GH
|
|
|
|
|
Title:
|
|
Ponatinib Is Active Against the CUX1-FGFR1 Fusion Kinase and Against
Imatinib Resistance Mutations of the FIP1L1-PDGFRa Fusion Kinase and
of KIT
|
|
Poster Session:
|
|
Myeloproliferative Syndromes: Poster III
|
|
Date & Time:
|
|
Monday, December 12, 2011, 6:00 - 8:00 p.m. (PST)
|
|
Abstract No.:
|
|
3848
|
|
Presenter:
|
|
Els Lierman, Ph.D. (Center for Human Genetics, Katholieke
Universiteit Leuven, Belgium)
|
|
Location:
|
|
Hall GH
|
|
|
|
|
Title:
|
|
Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3
Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD
Mutations
|
|
Oral Session:
|
|
Molecular Pharmacology, Drug Resistance: Targeting Chemoresistant
Cells and Niche
|
|
Date & Time:
|
|
Tuesday, December 13, 2011, 8:45 a.m. (PST)
|
|
Abstract No.:
|
|
930
|
|
Presenter:
|
|
Catherine C. Smith, M.D. (The University of California San Francisco)
|
|
Location:
|
|
Room 25
|
About ARIAD
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company
focused on the discovery, development and commercialization of medicines
to transform the lives of cancer patients. ARIAD's approach to
structure-based drug design has led to three internally discovered,
molecularly targeted product candidates for drug-resistant and
difficult-to-treat cancers, including certain forms of chronic myeloid
leukemia, soft tissue and bone sarcomas and non-small cell lung cancer.
For additional information, visit http://www.ariad.com.
SOURCE: ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc.
For Investors
Maria E. Cantor, 617-621-2208
Maria.cantor@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
